Vaccine and Immunisation Research Group clinical studies
Mid 2020 - 2021
Quadrivalent cell culture inactivated influenza vaccine Phase III/IV
RSV adenovirus vectored vaccine Phase I
Pneumococcal vaccine 15vPCV Phase III
Planned and possible studies
Meningococcus MenABCWY Phase III
Meningococcus MenABCWY Phase III (prior MenACWY)
Pregnancy RSV vaccine Phase III
COVID (SARS-CoV-2) vaccines Phase II
RSV Live-attenuated vaccine Phase II
Pertussis Live-attenuated vaccine Phase I/II
CMV Vaccine Study
CMV Vaccine Study Is Open for Recruitment
The Vaccine and Immunisation Research Group at the Doherty Institute, University of Melbourne is inviting healthy females aged 16 to 40 years to take part in a clinical research study looking at an investigational CMV vaccine.
Cytomegalovirus (CMV) is a virus which is a major health concern around the world. CMV is a contagious disease and can affect people of all age groups. However, unborn babies are at greater risk of serious illness and lifelong disability if their mother has her first CMV infection during pregnancy.
This clinical research study will look at the effectiveness of an investigational CMV vaccine in females of childbearing age.
You may be eligible to participate in this clinical trial if you are:
- - Aged 16 to 40 years
- - In good health,
- - Not pregnant or trying to get pregnant
- - Have direct contact with children 5 years of age and under for at least 8 hours per week
Participation will last for about 2.5 years and will include visits to the clinic and telephone calls to check your health. Reimbursement will be provided for travel and for your time.
For more information contact the Vaccine and Immunisation Research Group on email@example.com or (03) 8344 9325.
Professor Terry Nolan AO
+61 3 8344 8389 | firstname.lastname@example.org
- Head of Vaccine and Immunisation Research Group
- Immunology, Viral Infectious Diseases
- Clinical and health systems research
- The University of Melbourne, Department of Infectious Diseases
- Lab Group(s):
- Vaccine and Immunisation Research Group
Professor Terry Nolan AO FAHMS is a paediatrician and clinical epidemiologist, a medical graduate of the University of Western Australia, trained in paediatrics at the Royal Children’s Hospital in Melbourne and at the Montréal Children’s Hospital, with a PhD in epidemiology and biostatistics at McGill University in Montréal. He established the Clinical Epidemiology and Biostatistics Unit at the Royal Children’s Hospital in 1989, was promoted to Professor in 1999 and became Deputy Head of Paediatrics within the School of Medicine, and in 2001 was appointed Foundation Head of the Melbourne School of Population and Global Health. He was Associate Director of the Murdoch Children’s Research Institute in the late 1990s, and has continued an appointment to MCRI as a Professorial Research Fellow and head of the Vaccine and Immunization Research Group (VIRGo) since then. His research has been principally in immunisation and clinical trials of new vaccines. He has over 240 publications in refereed journals. He has considerable experience in working with both Australian and New Zealand Governments and with the World Health Organisation in the provision of policy advice. He served for 9 years on NHMRC’s Research Committee, including a 3-year term as its Deputy Chair. He chaired ATAGI for 9 years. He served a 6-year appointment on the WHO principal global advisory group on immunisation, SAGE (Scientific Advisory Group of Experts).